Chemobrain: A Pilot Study Exploring the Severity and Onset of Chemotherapy-Related Cognitive Impairment

Kelly Moore, Sonja Stutzman, Laurin Priddy, Daiwai Olson

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Chemotherapy-related cognitive impairment refers to a cluster of symptoms commonly referred to as "chemobrain". To date, nursing literature on the progression of and tools used to evaluate chemobrain is limited. OBJECTIVES: The purpose of this pilot study was to explore the onset of chemobrain in patients who recently began chemotherapy treatment, as well as those who have been receiving chemotherapy for an extended period of time. METHODS: This prospective, nonrandomized, observational pilot feasibility study used the General Practitioner Assessment of Cognition and the Trail Making Test Parts A and B to examine chemotherapy-related cognitive impairment symptoms in patients undergoing chemotherapy treatment. FINDINGS: Paired t tests showed a significant difference in scores on the Trail Making Test Part A from baseline to eight months (p < 0.05) and in scores on the Trail Making Test Part B from four to eight months (p < 0.05). The mixed results suggest that the Trail Making Test Parts A and B may not be effective for testing chemotherapy-related cognitive impairment in patients.

Original languageEnglish (US)
Pages (from-to)411-416
Number of pages6
JournalClinical journal of oncology nursing
Volume23
Issue number4
DOIs
StatePublished - Aug 1 2019

Fingerprint

Trail Making Test
Drug Therapy
Neurobehavioral Manifestations
Feasibility Studies
General Practitioners
Cognition
Cognitive Dysfunction
Nursing
Therapeutics

Keywords

  • antineoplastic combined chemotherapy protocols
  • cognitive impairment
  • oncology
  • symptom management

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Cite this

Chemobrain : A Pilot Study Exploring the Severity and Onset of Chemotherapy-Related Cognitive Impairment. / Moore, Kelly; Stutzman, Sonja; Priddy, Laurin; Olson, Daiwai.

In: Clinical journal of oncology nursing, Vol. 23, No. 4, 01.08.2019, p. 411-416.

Research output: Contribution to journalArticle

@article{d00ae1054fe74b34bc525c4927afc92b,
title = "Chemobrain: A Pilot Study Exploring the Severity and Onset of Chemotherapy-Related Cognitive Impairment",
abstract = "BACKGROUND: Chemotherapy-related cognitive impairment refers to a cluster of symptoms commonly referred to as {"}chemobrain{"}. To date, nursing literature on the progression of and tools used to evaluate chemobrain is limited. OBJECTIVES: The purpose of this pilot study was to explore the onset of chemobrain in patients who recently began chemotherapy treatment, as well as those who have been receiving chemotherapy for an extended period of time. METHODS: This prospective, nonrandomized, observational pilot feasibility study used the General Practitioner Assessment of Cognition and the Trail Making Test Parts A and B to examine chemotherapy-related cognitive impairment symptoms in patients undergoing chemotherapy treatment. FINDINGS: Paired t tests showed a significant difference in scores on the Trail Making Test Part A from baseline to eight months (p < 0.05) and in scores on the Trail Making Test Part B from four to eight months (p < 0.05). The mixed results suggest that the Trail Making Test Parts A and B may not be effective for testing chemotherapy-related cognitive impairment in patients.",
keywords = "antineoplastic combined chemotherapy protocols, cognitive impairment, oncology, symptom management",
author = "Kelly Moore and Sonja Stutzman and Laurin Priddy and Daiwai Olson",
year = "2019",
month = "8",
day = "1",
doi = "10.1188/19.CJON.411-416",
language = "English (US)",
volume = "23",
pages = "411--416",
journal = "Clinical Journal of Oncology Nursing",
issn = "1092-1095",
publisher = "Oncology Nursing Society",
number = "4",

}

TY - JOUR

T1 - Chemobrain

T2 - A Pilot Study Exploring the Severity and Onset of Chemotherapy-Related Cognitive Impairment

AU - Moore, Kelly

AU - Stutzman, Sonja

AU - Priddy, Laurin

AU - Olson, Daiwai

PY - 2019/8/1

Y1 - 2019/8/1

N2 - BACKGROUND: Chemotherapy-related cognitive impairment refers to a cluster of symptoms commonly referred to as "chemobrain". To date, nursing literature on the progression of and tools used to evaluate chemobrain is limited. OBJECTIVES: The purpose of this pilot study was to explore the onset of chemobrain in patients who recently began chemotherapy treatment, as well as those who have been receiving chemotherapy for an extended period of time. METHODS: This prospective, nonrandomized, observational pilot feasibility study used the General Practitioner Assessment of Cognition and the Trail Making Test Parts A and B to examine chemotherapy-related cognitive impairment symptoms in patients undergoing chemotherapy treatment. FINDINGS: Paired t tests showed a significant difference in scores on the Trail Making Test Part A from baseline to eight months (p < 0.05) and in scores on the Trail Making Test Part B from four to eight months (p < 0.05). The mixed results suggest that the Trail Making Test Parts A and B may not be effective for testing chemotherapy-related cognitive impairment in patients.

AB - BACKGROUND: Chemotherapy-related cognitive impairment refers to a cluster of symptoms commonly referred to as "chemobrain". To date, nursing literature on the progression of and tools used to evaluate chemobrain is limited. OBJECTIVES: The purpose of this pilot study was to explore the onset of chemobrain in patients who recently began chemotherapy treatment, as well as those who have been receiving chemotherapy for an extended period of time. METHODS: This prospective, nonrandomized, observational pilot feasibility study used the General Practitioner Assessment of Cognition and the Trail Making Test Parts A and B to examine chemotherapy-related cognitive impairment symptoms in patients undergoing chemotherapy treatment. FINDINGS: Paired t tests showed a significant difference in scores on the Trail Making Test Part A from baseline to eight months (p < 0.05) and in scores on the Trail Making Test Part B from four to eight months (p < 0.05). The mixed results suggest that the Trail Making Test Parts A and B may not be effective for testing chemotherapy-related cognitive impairment in patients.

KW - antineoplastic combined chemotherapy protocols

KW - cognitive impairment

KW - oncology

KW - symptom management

UR - http://www.scopus.com/inward/record.url?scp=85070075412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070075412&partnerID=8YFLogxK

U2 - 10.1188/19.CJON.411-416

DO - 10.1188/19.CJON.411-416

M3 - Article

C2 - 31322622

AN - SCOPUS:85070075412

VL - 23

SP - 411

EP - 416

JO - Clinical Journal of Oncology Nursing

JF - Clinical Journal of Oncology Nursing

SN - 1092-1095

IS - 4

ER -